Skip to main content
Premium Trial:

Request an Annual Quote

Atlas Biolabs to Offer Roche NimbleGen Target-Enrichment, Sequencing Services


This article was originally published Feb. 3.

Roche NimbleGen said today that it has certified genomics service provider Atlas Biolabs to provide target-enrichment and sequencing services using its technologies.

Atlas Biolabs, based in Berlin, will provide DNA capture services using NimbleGen Sequence Capture arrays, and then sequence the samples on Roche's 454 GS FLX.

In order to join Roche Nimblegen's certified service provider program, Atlas had to pass "a rigorous certification test plan to achieve precise experimental standards," according to the firm.

Atlas offers a number of high-throughput microarray-based services, including targeted genomic enrichment, expression analysis, SNP analysis, and CGH analysis. According to its website, the firm also uses technologies from Affymetrix, Agilent Technologies, and Illumina. For sequence enrichment, it also offers services using RainDance Technologies' microdroplet PCR technology.

Atlas Biolabs joins two other European NimbleGen-certified service providers: Eurofins MWG Operon and ImaGenes.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.